Physician profile
Karlee Davis
NPI 1609476480
$1,441.29
in general payments reported to CMS, 2019-2025
16 companies · $606 in 2025
The $606 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $349 · 2024: $486 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,441.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $273.24 | 2023-2024 | Repatha, Evenity, Otezla |
| Glaxosmithkline, LLC. | $229.60 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $201.63 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $128.82 | 2024-2025 | |
| Exact Sciences Corporation | $100.96 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $98.81 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $84.16 | 2023-2024 | Mounjaro, Jardiance, Emgality |
| Supernus Pharmaceuticals, INC. | $74.94 | 2023 | Qelbree, Xyosted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.69 | 2023-2024 | Xifaxan |
| Abbvie INC. | $57.70 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $28.52 | 2023-2024 | Steglatro, Lagevrio, Belsomra |
| Abbott Laboratories | $21.48 | 2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $21.43 | 2025 | Korlym |
| Boston Scientific Corporation | $20.77 | 2025 | Accolade Sr |
| Corium, LLC | $20.11 | 2023 | Azstarys |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $14.43 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karlee Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.